Annexon’s Financial Position Remains Strong Amid Losses Annexon reported a net loss of $138.2 million for 2024, with R&D expenses surging to $119.4 million for the year. Despite this, the company maintains $312 million in cash reserves, providing operational runway into late 2026, and continues advancing key clinical programs, including ANX005 for Guillain-Barré Syndrome.2